Form 4: Verona Pharma Director Exits Stake Post-Merck Acquisition

Verona Pharma director Vikas Sinha disposed of all his beneficial ownership in the company following its acquisition by Merck Sharp & Dohme LLC.

Summary

• Vikas Sinha, a director of Verona Pharma plc (VRNA), reported changes in his beneficial ownership.
• The changes occurred on October 7, 2025, as a result of the acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC and its subsidiary, Vol Holdings LLC.
• The acquisition was executed through a Scheme of Arrangement under the UK Companies Act 2006, based on a Transaction Agreement dated July 8, 2025.
• At the effective time of the Scheme, holders of Verona Pharma Ordinary Shares became entitled to receive $13.375 in cash per share.
• Holders of American Depositary Shares (ADSs), each representing eight Ordinary Shares, became entitled to receive $107 in cash per ADS.
• Mr. Sinha disposed of 94,112 Ordinary Shares and 72,000 Ordinary Shares through the Scheme of Arrangement.
• His Restricted Share Unit (RSU) awards, covering 72,000 Ordinary Shares (equivalent to ADSs), fully vested and converted into cash based on the ADS Consideration.
• His outstanding share options, totaling 400,384 Ordinary Shares (underlying ADSs) with various exercise prices, fully vested and converted into cash if their exercise price was less than the ADS Consideration.
• Following these transactions, Mr. Sinha's beneficial ownership in Verona Pharma plc is now zero.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person and shareholders as the acquisition provides a clear cash exit at a specified value, indicating a successful corporate event. It's neutral for the company's independent future as it's being acquired.

Positives

• Vikas Sinha received a cash payout for his equity holdings (Ordinary Shares, RSUs, and Share Options) as part of the acquisition.
• The acquisition provided a clear exit strategy and liquidity for shareholders, including the reporting person, at a fixed cash price of $13.375 per Ordinary Share or $107 per ADS.
• RSU awards and eligible share options fully vested and converted into cash, maximizing their value for the reporting person.

Negatives

• Vikas Sinha no longer holds any beneficial ownership in Verona Pharma plc, indicating a complete divestment of his stake.
• The company, Verona Pharma, will cease to be an independent publicly traded entity following the acquisition.

Risks

• The filing itself does not detail new risks for the company post-acquisition, as it focuses on the insider's transaction related to a completed acquisition. The primary risk for shareholders of Verona Pharma plc (VRNA) prior to the acquisition was the potential for the deal to fall through, but this filing indicates the transaction has reached its effective time.

Future Outlook

Verona Pharma plc is being acquired by Merck Sharp & Dohme LLC, and as such, its independent future outlook is now integrated into the acquiring entity. The filing details the finalization of this acquisition for the reporting person's equity.

Industry Context

The acquisition of Verona Pharma plc by a major pharmaceutical company like Merck Sharp & Dohme LLC highlights ongoing consolidation within the biopharmaceutical sector, where larger players seek to acquire promising assets or pipelines to bolster their portfolios. This transaction reflects a strategic move by Merck to potentially integrate Verona Pharma's assets, such as its lead product ensifentrine, into its broader therapeutic areas.

Corporate Governance

Related Party Transactions

• The acquisition itself, involving the disposition of shares by a director to the acquiring entity, can be considered a significant transaction impacting all shareholders and management as related parties to the corporate action.

Stakeholder Impact

• Shareholders: Received a cash payout of $13.375 per Ordinary Share or $107 per ADS, providing liquidity and a defined return on investment.
• Employees: Will be integrated into Merck Sharp & Dohme LLC, potentially leading to changes in roles, responsibilities, and corporate culture.
• Management (including Vikas Sinha): Their equity awards were converted to cash, and their roles within the acquired entity will likely be redefined or terminated.

Next Steps

• Integration of Verona Pharma plc into Merck Sharp & Dohme LLC's operations.
• Formal delisting of Verona Pharma plc's securities from public exchanges.

Key Dates

Keywords

Verona Pharma, VRNA, Merck Sharp & Dohme, Acquisition, Scheme of Arrangement, Insider Transaction, Form 4, Vikas Sinha, Beneficial Ownership, Restricted Share Units, Share Options, Pharmaceuticals